Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.38, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 38
- Publication Date: 2020
- Doi Number: 10.1016/j.msard.2019.101868
- Journal Name: MULTIPLE SCLEROSIS AND RELATED DISORDERS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Keywords: Neuromyelitis optica spectrum disorder, Therapy, Predictors, Relapses, Disability, Immunosuppression, OPTICA SPECTRUM DISORDER, NEUROMYELITIS-OPTICA, MULTIPLE-SCLEROSIS, CHINESE PATIENTS, AZATHIOPRINE, RITUXIMAB, EFFICACY, REGISTRY
- Karadeniz Technical University Affiliated: Yes
Abstract
Background: Aquaporin-4-IgG positive (AQP4-IgG(+)) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG + NMOSD are typically measured by relapse rate and disability. Using the MSBase, a multi-centre international registry, we aimed to examine the impact immunosuppressive therapies and patient characteristics as predictors of disease outcome measures in AQP4-IgG + NMOSD.